Concept: STAT3

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion

Resistance mechanisms to PARP inhibitor therapy in BRCA-mutant breast cancer